Astarte Medical, a Yardley, Pa.-based precision medicine company using software and predictive analytics to improve premature infant outcomes, secured $5m in Series A financing.
– Viking Global Investors LP,
– Lunsford Capital,
– OCA Ventures,
– Keiretsu Forum MidAtlantic,
– Keiretsu Capital Fund,
– Ben Franklin Technology Partners,
– Wing VC, and
– Next Act Fund.
The company, which recently graduated from the Illumina Accelerator, will use the funds to complete the development of its NICUtrition® suite of digital tools and diagnostics, which support feeding protocols, practice and decision-making in the neonatal ICU (NICU).
Led by Tracy Warren, CEO and Co-founder, Astarte Medical is a precision medicine company using software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants. NICUtrition® by Astarte Medical supports feeding protocols, practice and decision-making in the neonatal ICU with a suite of digital tools and diagnostics designed to standardize feeding, optimize nutrition and quantify gut health.
Core to its platform is its comprehensive and proprietary dataset that integrates feeding protocols, microbial profiles and clinical information.